

CA12 Antibody (C-term) Blocking Peptide
Synthetic peptide
Catalog # BP9812b**Specification**

CA12 Antibody (C-term) Blocking Peptide - Product Information

Primary Accession [O43570](#)

CA12 Antibody (C-term) Blocking Peptide - Additional Information

Gene ID 771

Other Names

Carbonic anhydrase 12, Carbonate dehydratase XII, Carbonic anhydrase XII, CA-XII, Tumor antigen HOM-RCC-313, CA12

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

CA12 Antibody (C-term) Blocking Peptide - Protein Information

Name CA12 ([HGNC:1371](#))

Function

Reversible hydration of carbon dioxide.

Cellular Location

Membrane; Single-pass type I membrane protein. Cell membrane

Tissue Location

Highly expressed in colon, kidney, prostate, intestine and activated lymphocytes. Expressed at much higher levels in the renal cell cancers than in surrounding normal kidney tissue Moderately expressed in pancreas, ovary and testis. Expressed in sweat glands and bronchiolar epithelium (PubMed:26911677)

CA12 Antibody (C-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

CA12 Antibody (C-term) Blocking Peptide - Images

CA12 Antibody (C-term) Blocking Peptide - Background

Carbonic anhydrases (CAs) are a large family of zinc metalloenzymes that catalyze the reversible hydration of carbon dioxide. They participate in a variety of biological processes, including respiration, calcification, acid-base balance, bone resorption, and the formation of aqueous humor, cerebrospinal fluid, saliva, and gastric acid. This gene product is a type I membrane protein that is highly expressed in normal tissues, such as kidney, colon and pancreas, and has been found to be overexpressed in 10% of clear cell renal carcinomas.

CA12 Antibody (C-term) Blocking Peptide - References

Liao, S.Y., et al. BMC Dev. Biol. 9, 22 (2009) Barnett, D.H., et al. Cancer Res. 68(9):3505-3515(2008) Haapasalo, J., et al. Neuro-oncology 10(2):131-138(2008) Pastorekova, S., et al. Curr. Pharm. Des. 14(7):685-698(2008) Kim, J.Y., et al. J. Cancer Res. Clin. Oncol. 132(5):302-308(2006)